Dental Asia November/December 2021
For more than two decades, Dental Asia is the premium journal in linking dental innovators and manufacturers to its rightful audience. We devote ourselves in showcasing the latest dental technology and share evidence-based clinical philosophies to serve as an educational platform to dental professionals. Our combined portfolio of print and digital media also allows us to reach a wider market and secure our position as the leading dental media in the Asia Pacific region while facilitating global interactions among our readers.
For more than two decades, Dental Asia is the premium journal in linking dental innovators
and manufacturers to its rightful audience. We devote ourselves in showcasing the latest dental technology and share evidence-based clinical philosophies to serve as an educational platform to dental professionals. Our combined portfolio of print and digital media also allows us to reach a wider market and secure our position as the leading dental media in the Asia Pacific region while facilitating global interactions among our readers.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Dental</strong> Updates<br />
<strong>Dental</strong>Monitoring launches ScanBox pro<br />
<strong>Dental</strong>Monitoring, the company that<br />
pioneered artificial intelligence in dental<br />
and orthodontic care, has launched the<br />
ScanBox pro . Built upon the success of<br />
their previous DM ScanBox, their latest<br />
FDA-registered innovation is a portable<br />
device that patients can take with them<br />
for precise AI-powered scans anytime and<br />
anywhere.<br />
This hardware accompanies the flagship<br />
software solution <strong>Dental</strong>Monitoring, a<br />
customisable cloud-based platform for<br />
remote clinical monitoring of orthodontic<br />
treatments designed to create a single<br />
automated workflow per patient and<br />
boost practice scalability.<br />
The device consists of two components<br />
— a cheek retractor tube designed to draw<br />
the cheeks and lips from the buccal and<br />
labial surfaces of the teeth and gums<br />
during scanning and a phone holder<br />
designed to accommodate a smartphone.<br />
Paired with the unique DM app for patients,<br />
the ScanBox pro offers:<br />
• Consistent imaging over time for precise<br />
tracking of treatment progress including<br />
aligners, braces and retainers of all brands<br />
• Excellent occlusal and lateral views,<br />
including molar occlusion<br />
• Increased portability<br />
• An adapted design for all patients from six<br />
years old<br />
• Easy storage capability with 41% less<br />
volume<br />
• Autoclavable capacity<br />
“We couldn’t be prouder to introduce our<br />
latest innovation as we continue to go<br />
further and break new ground with our<br />
solutions,” said Phillipe Salah, chief executive<br />
officer of <strong>Dental</strong>Monitoring. “The ScanBox pro<br />
is a game-changer for patients. It is<br />
lightweight, portable and can easily join them<br />
on-the-go, anywhere, for high-quality scans<br />
powered by the first and most robust AI in<br />
the industry. In turn, it allows doctors to have<br />
control at every stage of treatment and helps<br />
automate their workflow while enhancing their<br />
patient experiences.”<br />
The ScanBox pro is the newest addition to<br />
<strong>Dental</strong>Monitoring’s family of devices and<br />
software solutions including SmileMate, for<br />
engagement, triage and patient conversion;<br />
and <strong>Dental</strong>Monitoring, the only available AIbased<br />
remote monitoring solution available<br />
to both fixed and removable orthodontic<br />
appliances of all brands. ■<br />
FDA grants 510(k) market clearance to Vivos Therapeutics’ mmRNA Oral<br />
Appliance<br />
Vivos Therapeutics, Inc., a medical<br />
technology company focused on<br />
developing and commercialising innovative<br />
diagnostic and treatment modalities for<br />
patients suffering from sleep-disordered<br />
breathing, including mild to moderate<br />
obstructive sleep apnoea (OSA), has been<br />
granted 510(k) market clearance by the<br />
US Food and Drug Administration (FDA)<br />
to its Vivos’ mmRNA (modified mandibular<br />
Repositioning Nighttime Appliance) device.<br />
This FDA clearance paves the way for<br />
expanded insurance reimbursement<br />
coverage for the mmRNA device, including<br />
Medicare, as well as for potential future<br />
government contracts and reimbursement<br />
from commercial payers that follow<br />
Medicare guidelines.<br />
More than one billion people globally<br />
and 54 million Americans suffer from<br />
sleep apnoea, 80% of whom remain<br />
undiagnosed. A serious chronic illness, sleep<br />
apnoea increases the risk of comorbidities,<br />
including high blood pressure, heart failure,<br />
stroke, diabetes, dementia and other lifethreatening<br />
diseases. Vivos’ oral appliances<br />
address the dental tissue anomalies and<br />
malformations known to be associated<br />
with OSA. Unlike current standard-of-care<br />
interventions, patients treated with the Vivos<br />
System typically complete their therapy in<br />
12 to 24 months and, in most cases, do not<br />
require lifetime intervention.<br />
“The FDA’s market clearance of Vivos’<br />
newest device, the mmRNA appliance,<br />
represents a significant milestone in<br />
our ongoing efforts to provide the best<br />
possible treatment for people who<br />
continue to suffer needlessly from OSA,<br />
a debilitating condition that causes or<br />
contributes to a wide range of chronic<br />
health issues,” said Kirk Huntsman,<br />
chairman and chief executive officer<br />
of Vivos. “Next-generation products<br />
like the mmRNA are vital for allowing<br />
medical doctors and dentists to continue<br />
pushing forward in their joint mission<br />
to give patients a better alternative for<br />
effectively treating their OSA. Further,<br />
this FDA clearance for the mmRNA<br />
enables us to expand commercial<br />
insurance reimbursement, soon to<br />
include Medicare, making this a more<br />
cost-effective solution for patients<br />
suffering from OSA.” ■<br />
12<br />
DENTAL ASIA NOVEMBER / DECEMBER <strong>2021</strong>
Change language